WO1993018769A3 - Nouvelle utilisation d'un derive de quinazoline - Google Patents
Nouvelle utilisation d'un derive de quinazoline Download PDFInfo
- Publication number
- WO1993018769A3 WO1993018769A3 PCT/JP1993/000307 JP9300307W WO9318769A3 WO 1993018769 A3 WO1993018769 A3 WO 1993018769A3 JP 9300307 W JP9300307 W JP 9300307W WO 9318769 A3 WO9318769 A3 WO 9318769A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydroxy
- protected
- prolactin
- optionally substituted
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 nitro, amino, protected amino, hydroxyamino Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 208000010445 Chilblains Diseases 0.000 abstract 1
- 206010011703 Cyanosis Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 208000001034 Frostbite Diseases 0.000 abstract 1
- 208000001287 Galactorrhea Diseases 0.000 abstract 1
- 206010017600 Galactorrhoea Diseases 0.000 abstract 1
- 206010018265 Gigantism Diseases 0.000 abstract 1
- 206010020571 Hyperaldosteronism Diseases 0.000 abstract 1
- 206010020852 Hypertonia Diseases 0.000 abstract 1
- 206010020880 Hypertrophy Diseases 0.000 abstract 1
- 208000011707 Ovulation disease Diseases 0.000 abstract 1
- 208000015875 Pituitary gigantism Diseases 0.000 abstract 1
- 102000003946 Prolactin Human genes 0.000 abstract 1
- 108010057464 Prolactin Proteins 0.000 abstract 1
- 206010036831 Prolactin-producing pituitary tumour Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 208000001871 Tachycardia Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 229940097325 prolactin Drugs 0.000 abstract 1
- 201000002140 prolactin producing pituitary tumor Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000002889 sympathetic effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000006794 tachycardia Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
On décrit une utilisation d'un composé qui correspond à la formule (I) où R1 et R2 représentent chacun hydrogène, halogène, nitro, amino, amino protégé, hydroxyamino, alkyle inférieur, hydroxy, hydroxy protégé, sulfamoyle, carboxy, carboxy protégé, mercapto, carbonyle hétérocyclique éventuellement substitué, alkyle (inférieur) hétérocyclique éventuellement substitué, alkylthio inférieur, alkyle (inférieur) hydroxy ou alkyle (inférieur) hydroxy protégé; R3 représente aryle ou éventuellement son ou ses substituants appropriés, et A représente alkylène inférieur. Ce composé, ou un de ses sels acceptables sur le plan pharmaceutique se prête au traitement de différentes affections choisies dans le groupe consistant en hypertrophie cardiaque, néphropathies, telles que néphrite ou insuffisance rénale, artériosclérose oblitérante, thrombus obstructif, embole artériel, syndrome de Bürger-Grütz, acrocyanose, engelures, gelures, troubles de l'ovulation entraînant la production de prolactine, tumeur de l'hypophyse entraînant la production de prolactine, rétention lactée puerpérale, galactorrhée puerpérale, hypertrophie distale, gigantisme d'origine hypophysaire, troubles mentaux, maladies cérébro-vasculaires, tachycardie accompagnée d'hypertension sympathique, hyperaldostéronisme, et complications dues au diabète.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9205702.5 | 1992-03-16 | ||
| GB929205702A GB9205702D0 (en) | 1992-03-16 | 1992-03-16 | A new use of a quinazoline derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1993018769A2 WO1993018769A2 (fr) | 1993-09-30 |
| WO1993018769A3 true WO1993018769A3 (fr) | 1993-11-25 |
Family
ID=10712228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1993/000307 WO1993018769A2 (fr) | 1992-03-16 | 1993-03-15 | Nouvelle utilisation d'un derive de quinazoline |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB9205702D0 (fr) |
| WO (1) | WO1993018769A2 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2157208C2 (ru) * | 1997-07-10 | 2000-10-10 | Институт органической и физической химии им. А.Е.Арбузова Казанского научного центра РАН | Препарат для лечения отморожений |
| SG11201700776XA (en) | 2014-08-01 | 2017-02-27 | Nuevolution As | Compounds active towards bromodomains |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0436157A1 (fr) * | 1990-01-02 | 1991-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Dérivés de quinazoline et leur préparation |
| WO1993005035A1 (fr) * | 1991-09-06 | 1993-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Derives de quinazoline et leur preparation |
-
1992
- 1992-03-16 GB GB929205702A patent/GB9205702D0/en active Pending
-
1993
- 1993-03-15 WO PCT/JP1993/000307 patent/WO1993018769A2/fr active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0436157A1 (fr) * | 1990-01-02 | 1991-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Dérivés de quinazoline et leur préparation |
| WO1993005035A1 (fr) * | 1991-09-06 | 1993-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Derives de quinazoline et leur preparation |
Non-Patent Citations (3)
| Title |
|---|
| CARDIOVASCULAR DRUGS AND THERAPY vol. 4, no. S1, 1990, pages 73 - 84 C. COBO ET AL. ,V. COTO ET AL. , G.P. VYSSOULIS ET AL. 'EFFECTS OF KETANSERIN ON LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS, REGRESSION OF LEFT VENTRICULAR HYPERTROPHY AND SYSTOLIC FUNCTION IN HYPERTENSIVE PATIENTS DURING LONG-TERM TREATMENT WITH KETANSERIN, LEFT VENTRICULAR HYPERTROPHY REGRESSION AND FUNCTION CHANGES WITH KETANSERIN ...' * |
| GENERAL PHARMACOLOGY vol. 20, no. 6, 1989, pages 755 - 758 M. MIDOL-MONNET ET AL. 'STUDY ON THE MECHANISM OF 5-HT-INDUCED TACHYCARDIA IN THE PITHED RAT' * |
| JOURNAL OF CARDIOVASCULAR PHARMACOLOGY vol. 7, no. S7, 1985, pages S70 - S75 S. SAMAN ET AL. 'SEROTONIN AND THE HEART: EFFECTS OF KETANSERIN ON MYOCARDIAL FUNCTION, HEART RATE, AND ARRHYTHMIAS' * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB9205702D0 (en) | 1992-04-29 |
| WO1993018769A2 (fr) | 1993-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL332946A1 (en) | 1-phenylpyrazole compounds and their pharmaceutic application | |
| CA2432872A1 (fr) | Composes de pyrazole utiles comme inhibiteurs de proteines kinases | |
| WO2000008048A3 (fr) | Inhibiteur d'histone déacétylase | |
| EP0487745A4 (en) | Pyridine derivative with angiotensin ii antagonism | |
| DK1063228T5 (da) | Cycloalkenderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf | |
| AU3191995A (en) | Fused pyridazine compound | |
| WO2002072578A3 (fr) | Composes de quinoline heterocycliques contenant de l'azote | |
| DK0711282T3 (da) | Forbindelser som PDE IV og TNF inhibitorer | |
| CA2080705A1 (fr) | Derives de substitution de pyrimidines | |
| DK0841929T3 (da) | Quinoloner og deres terapeutiske anvendelse | |
| EP0555478A4 (en) | Pyrimidine derivative and medicine | |
| ES548418A0 (es) | Un procedimiento para preparar un compuesto de piperazina | |
| WO2000068198A3 (fr) | Derives de pyridine heterosubstitues utilises comme inhibiteurs de pde 4 | |
| NO941977L (no) | Indolderivater, fremgangsmåte for fremstilling av disse, og medisinsk anvendelse derav | |
| KR950704314A (ko) | 1,8-나프티리딘-2-온 유도체 및 그 사용 방법(1,8-naphthyridin-2-one derivative and use thereof) | |
| EP0434057A3 (en) | Indolocarbazole derivatives, processes for their preparation and their use | |
| PT96404A (pt) | Processo para a preparacao de novos derivados de quinazolina e de composicoes farmaceuticas que os contem | |
| CA2139731A1 (fr) | 5-hydroxy-1,3 pyrimidines a groupement heterocyclique en position 2 utilises comme agents anti-inflammatoires | |
| WO1993018769A3 (fr) | Nouvelle utilisation d'un derive de quinazoline | |
| EP0661274A1 (fr) | Dérivés d'indane, procédé pour leur préparation et leurs intermédiaires de synthèse | |
| WO2002062798A3 (fr) | Sels de composes heterocycliques pharmaceutiquement acceptables | |
| WO2000003978A3 (fr) | Benzolsulfonyl-urees et -thiourees substituees en 2,5, leur procede de production, leur utilisation et les preparations pharmaceutiques les contenant | |
| EP0201349A3 (fr) | Dérivés de tétrazole | |
| Foye et al. | Antiradiation compounds XVI: N‐heterocyclic aminoethyl disulfides and aminoethanethiosulfuric acids | |
| JPS5697226A (en) | Blood platelet coagulation inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| 122 | Ep: pct application non-entry in european phase |